University Eye Clinic Dresden
Dresden, Saxony, 01307, Germany
NCT Number: NCT01363362
Selective Laser Trabeculoplasty (SLT) is known to reduce intraocular pressure in glaucoma patients. This study investigates, if there are changes in different ocular hemodynamic parameters prior and after SLT.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Dresden, Saxony, 01307, Germany
Ocular blood flow, ocular pulse amplitude and ocular pulse volume are measured with the Blood Flow Analyzer (Paradigm Medical Industries, Inc.) prior and 3 month after SLT.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
Other names: Lasertrabeculoplasty
Time frame: baseline and 3 month
Pulsatile ocular blood flow, ocular pulse amplitude and ocular pulse volume are measured prior and 3 month after SLT with the Blood Flow Analyzer (Paradigm Medical Industries, Inc.)
Technische Universität Dresden
Other
Effect of Selective Lasertrabeculoplasty (SLT) on Ocular Hemodynamics in Glaucoma
Acronym: SLT/OBF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06960629
Corneal Diseases, Corneal Edema
Zagreb, Croatia
View Trial DetailsNCT07730424
Eye Diseases, Glaucoma
Fitzroy, Victoria, Australia
View Trial DetailsNCT07168902
Eye Diseases, Glaucoma
Glendale, California, United States
View Trial DetailsNCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial Details